PHARMACEUTICAL EXECUTIVE NEWSLETTER

In this ISSUE

Food and Pharma: The Broadening Reach of Regulators

"Drug Transparency": Each Bill Needs Careful Evaluation

UK Biopharma: Life After Brexit

Top Story

FDA, Industry Seek Speedy Congressional Approval of New User Fee Plan

Pharma and biotech companies want Congress to approve a new version of the Prescription Drug User Fee Act before leaving Washington at the end of the year
... /Read more/

NORD's Rare Diseases and Orphan Products Breakthrough Summit is the most meaningful multi-stakeholder event – historically featuring over 20 speakers from the FDA, participation from over 80 patient organizations and the Pharma/Biotech industry's foremost experts in orphan product innovation, investment and commercialization.
The 2016 Summit is your opportunity to address the progress and innovations in rare disease diagnosis, treatment, engagement and access of orphan products.

Learn more

Europe

England's New Cancer Drug Fund

A ‘new’ version of England's Cancer Drug Fund came into force last week. Leela Barham looks at how it's evolved since 2010
... /Read more/

Breaking the Circle of Distrust with a Radical PLC Pricing Model
On Demand

Learn more

Social Media & Marketing

The Answer is Video. Now What Was the Question?

Increasingly, media and marketing companies are looking to online video to rescue shrinking advertising rates and capture coveted social traffic. Peter Houston reports
... /Read more/

Best Practices for Integrating Biomarkers across the Drug Development Continuum
On Demand

Learn more

Interview

Habib Dable, President, US Pharmaceuticals, Bayer

Pharm Exec sits down with Habib Dable, a 22-year veteran of Bayer, to discuss his first few months at the helm of the company's US pharma operations
... /Read more/

Calendar

/ September 15–16: Compliance Congress for Specialty Products /

Boston, MA

/ October 5: Drug, Chemical & Associated Technology Association (DCAT) After the Show /

Barcelona, Spain

/ October 27–28: MedComm 2016 /

San Francisco, CA

/ December 13–14: Life Sciences Trade and Channel Strategies /

Philadelphia, PA

/ February 22–23, 2017: Speaker Programs 2017 /

Philadelphia, PA

Industry update

//Biotica Pharmaceuticals, Inc. (St. Petersburg, FL) named former Abbott exec Dr. P.C. Sundareswaran as President & CEO.//Cempra, Inc. (Chapel Hill, NC) appointed John Bluth to the newly created position of Executive Vice President, Investor Relations and Corporate Communications.//Accera, Inc. (Boulder, CO) named C. Evan Ballantyne as Chief Financial Officer.//

advertise with us / print subscribe / digital subscribe / visit pharmexec.com